CTMX vs AGEN

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -44. 8% for CytomX Therapeutics, Inc. (CTMX). Analysts rate CytomX Therapeutics, Inc. (CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CytomX Therapeutics, Inc.

(CTMX) delivered a total return of -53. 2%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: CTMX returned -67. 1% versus AGEN's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CytomX Therapeutics, Inc.

(CTMX) is the lower-risk stock at 1. 47β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 76% more volatile than CTMX relative to the S&P 500.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -44. 8% for CytomX Therapeutics, Inc. (CTMX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -139. 5% for CytomX Therapeutics, Inc.. Over a 3-year CAGR, CTMX leads at 12. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agenus Inc.

(AGEN) is the more profitable company, earning 0. 1% net margin versus -22. 8% for CytomX Therapeutics, Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGEN leads at -18. 0% versus -25. 7% for CTMX. At the gross margin level — before operating expenses — CTMX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CTMX: 190.

0% to $11. 60.

In this comparison, CTMX (0.

5% yield) pays a dividend. AGEN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CytomX Therapeutics, Inc.

(CTMX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 5% yield). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTMX: -67. 1%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CTMX pays a dividend while AGEN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.